李寶力 博士，副研究員，博士生導師，365英国上市官网在线副院長和工會副主席。其所在團隊構建了具有獨特研究風格的，含1400種已上市化學藥物的實體庫和含1370種藥用植物的提取物庫，通過多學科交叉合作，針對衰老及相關疾病、耐藥緻病菌感染等臨床急需領域，初步建立了“老藥二次開發”體系：發現新用途老藥先導、确證作用機制或靶标（晶體結構）、開展老藥二次優化改造與研發。近5年來，在Journal of Medicinal Chemistry、Acta Pharmaceutica Sinica B、European Journal of Medicinal Chemistry等期刊發表SCI論文18篇；已申請發明專利14項（含PCT專利1項），其中已授權國際專利3項和中國專利3項；主持國自然青年基金1項、國自然地區基金1項、海南省自然青年基金1項、海南大學高層次人才啟動經費1項、海南大學協同創新經費1項，參與國自然重點項目1項（子課題負責人，分配經費115萬）、國自然面上基金1項、美國Bankhead-Coley基金1項（450萬）、與海南中藤科技股份有限公司開展橫向合作（1000萬元）；參編《藥學英語》教材（副主編）。其所設計合成的候選新藥JX08-2，以1.4億元轉讓給麗珠醫藥集團股份公司。

 郵箱： baolili@hainanu.edu.cn

1. 教育背景

 2018.09 — 2021.09：墨菲特癌症研究中心，藥物開發部，博士後研究員；

 2013.09 — 2018.06：華東理工大學，365英国上市官网在线，藥學專業，博士（碩博連讀）；

 2009.09 — 2013.06：華東理工大學，365英国上市官网在线，藥物制劑專業、英語專業，雙學士。

2.研究領域

藥物化學合成、分子設計、靶标發現及作用機制研究

3.教學情況

藥物化學、藥學英語

4.社會兼職

中國災害防禦協會應急救援藥物和特醫食品分會副秘書長

中國中醫藥信息學會中醫臨床藥學分會常務理事

《藥學學報》、《Acta Pharmaceutica Sinica B》中英文兩刊青年編委

《Acta Materia Medica》青年編委

《中國藥物化學雜志》首屆青年編委

5．發表論文 (†第一作者、并列第一作，*通訊作者)

1）Zhifan Mao†, Wenwen Liu†, Rong Zou†, Ling Sun†, Lingyu Wu, Liru Chen, Zhouzhi Song, Shuman Huang, Yunyuan Huang, Yong Rao, Yi-You Huang, Baoli Li*, Zelan Hu*, and Jian Li*. Glibenclamide targets MDH2 to relieve aging phenotypes through metabolism-regulated epigenetic modification. Signal Transduction and Targeted Therapy, 2025,10,67.

2）Taotao Lu†, Hongguang Han†, Chaohui Wu†, Qian Li, Hongyan Hu, Wenwen Liu, Donglei Shi, Feifei Chen, Lefu Lan, Jian Li*, Shihao Song*, Baoli Li*. Discovery of a novel polymyxin adjuvant against multidrug-resistant Gram-negative bacteria through oxidative stress modulation. Acta Pharmaceutica Sinica B, 2025, 15(3), 1680-1695.

3）Lingyu Wu†, Yingying Wu†, Shangding Yang†, Siyu Jin†, Qing Zhang, Zhongbin Cheng, Chaohui Wu, Yiming Hao, Ling Sun, Wenwen Liu, Donglei Shi, Jian Li, Yi-You Huang*, Baoli Li*, and Hai-Bin Luo*. Discovery of Extracts and Wedelolactone from Eclipta Prostrata (L.) Linn. as a Natural PDE4 Inhibitors with Potent anti-Psoriasis Effects. Acta Materia Medica, 2025. (Accepted)

4)Qing Zhang†, Ling Sun†, Lingyu Wu†, Xue Wang, Liru Chen, Youyou Chen, Yuhang Liu, Wenhui Gu, Donglei Shi, Wenwen Liu, Jian Li, Yi-You Huang*, Baoli Li*, and Hai-Bin Luo*. Platycladus orientalis (L.) Franco Demonstrates Effective anti-psoriasis effects by Inhibiting PDE4 with Favorable Safety Profiles. Chinese Chemical Letters, 2024,doi.org/10.1016/j.cclet.2024.110795，（online）.

5）Taotao Lu†, Manjiong Wang†, Yunyuan Huang†, Donglei Shi, Xiao Li, Jiaqi Liu, Jian Li, Bei Jiang*, Baoli Li*, Yixiang Xu*. The efficacy and mechanisms of Euphorbia neriifolia Linn extracts for the treatment of heart failure. Arabian Journal of Chemistry, 2024 (under revision).

6）Xiao Li†, Yue Yao†, Luoyifan Zhou†, Jin Yang, Xin Chen, Chao Zhang, Manjiong Wang, Jian Li*, Baoli Li*, and Yixiang Xu*. Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects. Acta Materia Medica, 2024, 3(2), 133-146.

7）Haolan You†, Yihe Song†, Yi Yang†, Xicheng Wang, Shiqi Pan, Junyang Huang, Qiqi Shao, Donglei Shi, Baoli Li*, Jian Li*, Xiaokang Li*. European Journal of Medicinal Chemistry. 2024，278，116800

8）Ru Zeng, Taotao Lu, Lingyu Wu, Qing Zhang, Donglei Shi, Jian Li, Shihao Song*, Baoli Li*. Structural modification and activity evaluation of sensitizers against drug-resistant Pseudomonas aeruginosa DK2. Journal of Shenyang Pharmaceutical University 2023, 40, 1587-1597.

9）Taotao Lu†, Xinyu Zheng†, Fei Mao, Qiao Cao, Qin Cao, Jin Zhu, Lefu Lan*, Baoli Li*, Jian Li*, Novel niclosamide-derived adjuvants elevating the efficacy of polymyxin B against MDR Pseudomonas aeruginosa DK2, European Journal of Medicinal Chemistry. 2022, 236, 114318.

10）Xinming Li, Donglei Shi, Yihe Song, Yixiang Xu, Ying Gao, Wenjing Qiu, Xin Chen, Xiaokang Li, Yunyuan Huang, Yanjun Feng, Baoli Li*, Yuan Guo*, Jian Li*, Specific tracking of monoamine oxidase A in HF models by a far-red fluorescent probe with an ultra large Stokes shift, Chinese Chemical Letters, 2021, 33, 1572-1576.

11）Ryan R Davis, Baoli Li, Sang Y Yun, Alice Chan, Pradeep Nareddy, Steven Gunawan, Muhammad Ayaz, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, Ernst Schönbrunn*, Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof, Journal of Medicinal Chemistry, 2021, 64, 2228-2241.

12）Keting Bao, Yongyun Li, Jinlian Wei, Ruoxi Li, Jie Yang, Jiahao Shi, Baoli Li, Jin Zhu, Fei Mao, Renbing Jia, and Jian Li. Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway. Cell Death and Disease. 2021, 12, 380.

13）Xin Chen, Xi Yang, Fei Mao, Jinlian Wei, Yixiang Xu, Baoli Li, Jin Zhu, Shuaishuai*, Lijun Jia*, Jian Li*. Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo. European Journal of Medicinal Chemistry. 2021, 210, 112964.

14）Xiaokang Li†, Jian Lu†, Yixiang Xu†, Jiaying Wang, Xiaoxia Qiu, Lei Fan, Baoli Li, Wenwen Liu, Fei Mao, Jin Zhu, Xu Shen*, Jian Li*, Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer's disease, Acta Pharmaceutica Sinica B, 2020, 10, 646-666.

15）Shuaishuai Ni†, Xin Chen†, Qing Yu†, Yixiang Xu, Zhiguo Hu, Junqian Zhang, Wenjuan Zhang, Baoli Li, Xi Yang, Fei Mao, Jing Huang, Yi Sun, Jian Li*, Lijun Jia*, Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth, European Journal of Medicinal Chemistry, 2020, 185, 111848.

16）Shuaishuai Ni†, Baoli Li†, Yixiang Xu†, Fei Mao, Xiaokang Li, Lefu Lan, Jin Zhu, Jian Li*, Targeting virulence factors as an antimicrobial approach: Pigment inhibitors, Medicinal Research Reviews, 2020, 40, 293-338.

17）Hanwen Wei†, Fei Mao†, Shuaishuai Ni†, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao, Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections, European Journal of Medicinal Chemistry, 2018, 145, 235-251.

18）Shuaishuai Ni†, Baoli Li†, Feifei Chen†, Hanwen Wei, Fei Mao, Yifu Liu, Yixiang Xu, Xiaoxi Qiu, Xiaokang Li, Wenwen Liu, Linghao Hu, Dazheng Ling, Manjiong Wang, Xinyu Zheng, Jin Zhu*, Lefu Lan*, Jian Li*, Novel staphyloxanthin inhibitors with improved potency against multidrug resistant staphylococcus aureus, ACS Medicinal Chemistry Letter, 2018, 9, 233-237.

19）Baoli Li†, Shuaishuai Ni†, Fei Mao†, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*, Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity, Journal of Medicinal Chemistry, 2018, 61, 224-250.

20）Baoli Li†, Shuaishuai Ni†, Feifei Chen, Fei Mao, Hanwen Wei, Yifu Liu, Jin Zhu, Lefu Lan*, Jian Li*, Discovery of potent benzocycloalkane derived diapophytoene desaturase (CrtN) inhibitors with enhanced safety profile for the treatment of MRSA, VISA and LRSA infection, ACS Infectious Disease, 2018, 4, 208-217.

21）Baoli Li†, Xinyu Zheng, Manjiong Wang, Keting Bao, Fei Mao*. Synthesis and antitumor activity of δ-lactam compounds. Chinese Journal of Medicinal Chemistry, 2018, 03, 173-183.

22）Shuaishuai Ni†, Hanwen Wei†, Baoli Li†, Feifei Chen, Yifu Liu, Wenhua Chen, Yixiang Xu, Xiaoxia Qiu, Xiaokang Li, Yanli Lu, Wenwen Liu, Linhao Hu, Dazheng Lin, Manjiong Wang, Xinyu Zheng, Fei Mao, Jin Zhu, Lefu Lan*, Jian Li*, Novel inhibitors of staphyloxanthin virulence factor in comparison with linezolid and vancomycin versus methicillin-resistant, linezolid-resistant, and vancomycin-intermediate staphylococcus aureus infections in vivo, Journal of Medicinal Chemistry, 2017, 60, 8145-8159.

23）Sheng Ma†, Jing Deng†, Baoli Li†, Xiujiang Li, Zhaowei Yan, Jin Zhu, Gang Chen, Zhong Wang*, Hualiang Jiang, Liyan Miao*, Jian Li*. Development of second-generation small-molecule RhoA inhibitors with enhanced water solubility, tissue potency, and significant in vivo efficacy, ChemMedChem, 2015, 10, 193-206.

24）Baoli Li†, Fang Xiao*, Wenchao Lu, Yuyun Sun, Jin Zhu, Jian Li*, Discovery and synthesis of N2, N4-substitued-cycloalkyl [d] pyrimidine-2, 4-diamine analogs: The first examples of small-molecular FGFR-1, Chinese Chemical Letters, 2014, 25, 989-994.

6．已授權發明專利

1） 李劍、藍樂夫、倪帥帥、陳菲菲、魏漢文、劉毅夫、李寶力、毛斐、朱進；苯并含氧脂肪環甲胺類化合物，2021年1月13日，中國，ZL201611073277.2.

2） Li, Jian; Lan, Lefu; Li, Baoli; Chen, Feifei; Ni, Shuaishuai; Liu, Yifu; Wei, Hanwen; Mao, Fei; Zhu, Jin. BENZOHETEROCYCLYL ALKYLAMINE COMPOUNDS AND USE THEREOF. 2020年11月10日, US, 10829464.

3） 李劍；藍樂夫；李寶力；陳菲菲；倪帥帥；劉毅夫；魏漢文；毛斐；朱進；苯并雜環環烷基胺類化合物及其用途，2020年8月18日, 中國，ZL201611037724.9.

7．榮譽獎勵

教育部自然科學一等獎（2022）

上海市優秀共青團員（2015）

第八屆“挑戰杯”中國大學生創業計劃競賽銅獎（2012）

 歡迎具有藥學、化學、生物學背景的同學報考本課題組研究生。